BrosMed Announces CE Mark and Launch for Minerva™ Balloon Dilatation Catheter
Release time:
2015-04-14
April 14, 2015—BrosMed announced CE Mark and Launch of its Minerva™ percutaneous transluminal angioplasty (PTA) dilatation catheter for the treatment of patients with peripheral arterial disease.
April 14, 2015—BrosMed announced CE Mark and Launch of its Minerva™ percutaneous transluminal angioplasty (PTA) dilatation catheter for the treatment of patients with peripheral arterial disease.
As part of the BrosMed Medical balloon catheter portfolio, this generation, high-performance workhorse 0.018-inch semi-compliance PTA balloon catheter is intended to dilate stenoses in iliac, femoral, iliofemoral, popliteal, infrapopliteal, and renal arteries. It is also indicated for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae and for postdilation of balloon-expandable and self-expanding stents in the peripheral vasculature.
According to the company, the Minerva™ catheter is designed to provide outstanding crossability with a comprehensive selection of balloon sizes on its 0.018-inch over-the-wire platform. The device is available in balloon diameters of 1.5 to 10 mm and lengths of 5 to 200 mm, and the catheter lengths available of 70cm, 90cm and 150cm. Minerva™ combines a state of art engineered balloon technology, superior hydrophilic coating with a low-profile body and unique manicured tip design to enhance crossability and pubshability. Constructed with engineered material, the catheter has consistent rated burst pressures of 14atm from 1.5 to 10mm.
“The launch of Minerva™ PTA balloon dilatation catheter expands our balloon product portfolio from current cardiovascular filed to the endovascular filed. As acknowledged from cardiovascular market, the world smallest PTA balloon size of 1.5x5mm is available for tough and tortious lesion ever treated before.” said by Jos A.W.J de Korte, General Manager of BrosMed Medical B.V., the marketing and sales center of BrosMed Medical in Europe.
Please contact our regional distributors and/or our sales at sales@brosmed.com for products details.
About BrosMed Medical
BrosMed Medical is more than just a company; we are leading the medical device design and manufacturing revolution.
BrosMed Medical develops, manufactures and markets medical devices primarily used by interventional cardiologists, radiologists and vascular surgeons in angioplasty procedures and other minimal invasive devices.
We provide solutions to our customers through innovative design, effective supply chain management, world-class manufacturing, and flexible channels of distribution and through the development or acquisition of innovative technologies.
Join with Us!
Please fill out this form and we will get in touch within 24 hours.
* Note: Please be sure to fill in the information accurately and keep the communication unblocked. We will get in touch with you as soon as possible.
More news
BrosMed Announced CE MDR Approval of New Generation Conger™ Plus Hydrophilic Guidewires
Designed for superior crossability and maneuverability in peripheral interventions, Conger Plus now offers 116 models with expanded sizes (OD 0.018'' to 0.038'') and lengths (up to 300cm).
2025-04-25
Meet BrosMed at ESC Congress 2024
BrosMed Medical is delighted to participate in the ESC Congress 2024 from August 30th to September 2nd in London, UK.
2024-08-15
BrosMed Medical Announces Scott J. Addonizio as Chief Operating Officer
2024 August 1st – BrosMed Medical is pleased to announce the appointment of Scott J. Addonizio as its Chief Operating Officer (COO), effective immediately. Mr. Scott J. Addonizio brings a wealth of experience and expertise to BrosMed, with a distinguished career spanning almost 30 years in the medical device industry. Prior to joining BrosMed, Mr. Addonizio served as SVP at Cordis and COO at MedAlliance Swiss Medical Technology.
2024-08-01
CTO&CHIP PCI – Insights from the clinical practice (Ⅱ)
July 30, 2024 @16:00-17:30 (Beijing Time) Join BrosMed Medical on Tuesday, July 30 for an enlightening discussion that unites cardiologists from Malaysia, China, India, Tunisia and Portugal, where clinical expertise harmoniously fuses with CTO&CHIP innovation. At this exclusive webinar, we’re orchestrating a confluence of valuable insights, drawing from the collective wisdom of seasoned interventional cardiologists.
2024-07-26
BrosMed Announced CE MDR Approval of New Generation PTA SC Balloon Dilatation Catheters
May 27, 2024- BrosMed announced that it receives European Medical Device Regulation (MDR) certification for the New Generation PTA SC Balloon Dilatation Catheters (Brand Name: Polux™ Pro 014, Minerva™ Pro 018 and Atropos™ Pro 035).
2024-05-27